Arrowstreet Capital, Limited Partnership Glycomimetics Inc Transaction History

Arrowstreet Capital, Limited Partnership

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$2.69 - $4.24 $94,696 - $149,260	-35,203 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$3.07 - $5.0 $151,618 - $246,935	-49,387 Reduced 58.38%	35,203 $108,000
Q2 2020 Aug 12, 2020	SELL	$2.06 - $3.76 $90,590 - $165,349	-43,976 Reduced 34.2%	84,590 $318,000
Q1 2020 May 15, 2020	SELL	$1.83 - $5.41 $276,426 - $817,196	-151,053 Reduced 54.02%	128,566 $293,000
Q4 2019 Feb 13, 2020	BUY	$4.03 - $6.5 $1.13 Million - $1.82 Million	279,619 New	279,619 $1.48 Million

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.